PRIMERICA HOUSEHOLD BUDGET INDEX™ (HBI™): Purchasing Power for Middle-Income Americans Up Slightly in July

PRIMERICA HOUSEHOLD BUDGET INDEX™ (HBI™): Purchasing Power for Middle-Income Americans Up Slightly in July

DULUTH, Ga.–(BUSINESS WIRE)–
The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life’s everyday necessities, is estimated at 100.5% in July, an increase of 0.4% from June and also up 0.4% from a year ago.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826011714/en/

The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life’s everyday necessities, is estimated at 100.5% in July, an increase of 0.4% from June and also up 0.4% from a year ago. Lower gas prices for the second consecutive month provided modest relief for middle-income budgets. In addition, average earned income rose 0.2% month-over-month and increased 2.1% year-over-year.

The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life’s everyday necessities, is estimated at 100.5% in July, an increase of 0.4% from June and also up 0.4% from a year ago. Lower gas prices for the second consecutive month provided modest relief for middle-income budgets. In addition, average earned income rose 0.2% month-over-month and increased 2.1% year-over-year.

Lower gas prices for the second consecutive month provided modest relief for middle-income budgets. In addition, average earned income rose 0.2% month-over-month and increased 2.1% year-over-year.

The Consumer Price Index (CPI), which measures inflation for a comprehensive basket of goods for all U.S. households, increased 3.4% in July compared to a year ago. The cost of necessity items as used in the HBI™ metric (food, utilities, gas, auto insurance, and health care) for middle-income Americans is up 3.7% from a year ago.

About the Primerica Household Budget Index™ (HBI™) Data

The Primerica Household Budget Index™ (HBI™) data is constructed monthly on behalf of Primerica by its chief economic consultant Amy Crews Cutts, PhD, CBE®. The index measures the purchasing power of middle-income families with household incomes from $30,000 to $130,000 and is developed using data from the U.S. Bureau of Labor Statistics, the U.S. Bureau of Census, and the Federal Reserve Bank of Kansas City. The index looks at the cost of necessities including food, gas, auto insurance, utilities, and health care and earned income to track differences in inflation and wage growth.

Primerica’s HBI™ metric was created to fill an information void around the economy’s impact on middle-income families. Metrics like the Consumer Price Index (CPI) measure overall inflation but don’t offer a clear picture of how it impacts middle-income Americans. Middle-income households play a key role in driving consumer spending and the overall economy as they account for over 55% of the U.S. population. The purchasing power of middle-income families are a key barometer of real-time economic trends. Understanding middle-income households’ purchasing power is important because it shows whether they are gaining financial ground or falling behind.

The HBI™ data uses January 2019 as its baseline, with the value set to 100% at that point in time.

Periodically, prior HBI™ values may be modified due to revisions in the CPI series and Consumer Expenditure Survey releases by the U.S. Bureau of Labor Statistics (BLS). Beginning with the December 2024 release of the index, the expenditure weights have been updated to the most recent (Q1 2024) data and auto insurance has been added to the group of necessity items. For more information, visit householdbudgetindex.com.

About Primerica, Inc.

Primerica, Inc. is a leading diversified financial services distribution company serving middle-income households in the United States and Canada. Our licensed representatives educate families on how to prepare for a more secure financial future and help them achieve their financial goals with our term life insurance and third-party mutual funds, managed accounts, annuities, loans and other financial products. We insured over 5.5 million lives and had approximately 3.1 million client investment accounts as of December 31, 2025. Through our life insurance subsidiaries in North America, in 2025 Primerica was the #3 issuer of term life insurance, which we largely reinsure. Primerica stock is included in the S&P MidCap 400 and the Russell 1000 stock indices and is traded on The New York Stock Exchange under the symbol “PRI”. We are headquartered in Duluth, Georgia.

Media Contact:

Gana Ahn

678-431-9266

Email: [email protected]

Investor Contact:

Nicole Russell

470-564-6663

Email: [email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Consulting Banking Personal Finance Professional Services Other Energy Utilities Oil/Gas Data Analytics Insurance Energy Finance

MEDIA:

Photo
Photo
The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life’s everyday necessities, is estimated at 100.5% in July, an increase of 0.4% from June and also up 0.4% from a year ago. Lower gas prices for the second consecutive month provided modest relief for middle-income budgets. In addition, average earned income rose 0.2% month-over-month and increased 2.1% year-over-year.
Photo
Photo
The latest Primerica Household Budget Index™ (HBI™) data, a monthly economic metric that examines how inflation and wage trends impact the ability of middle-income families to afford life’s everyday necessities, is estimated at 100.5% in July, an increase of 0.4% from June and also up 0.4% from a year ago. Lower gas prices for the second consecutive month provided modest relief for middle-income budgets. In addition, average earned income rose 0.2% month-over-month and increased 2.1% year-over-year.
Logo
Logo

Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027

Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027

  • Numerous announcements made today as FF holds Part One of its FF EAI Robotics “Built in USA” Business Partner Conference, highlighting—the “Four-Core Full-Stack AI” Ecosystem Downstream Partner recruitment and the EAI Education Ecosystem milestone showcase & nationwide expansion session.

  • FF announced that its first two new EAI Devices selected for the “Built in USA” program are the full-size humanoid Next Futurist and the quadruped Next Aegis. FF will also officially launch several new additions to the FF EAI Robot World on September 19.

  • FF announced upgrades to its EAI robotics education ecosystem and has completed the initial development of version 1.0 of FF’s Industry Productivity Solution for the EAI Education Ecosystem. It will officially launch on September 19.

  • FF will launch the “EAI Robotics Made in USA” Global Industry Alliance initiative to build an ecosystem that is “Built in USA. Benefit the World.” FF plans to invest no less than $5 billion in the United States over the next ten years, while launching and manufacturing three to five new and next-generation robotics products in the United States each year.

  • Effective immediately, FF is opening nationwide recruitment for distributor partners, industry solution partners and developers, AI partners, and data and Skills partners.

  • RoboShare is officially opening partner recruitment across North America, with the goal of building the robot-sharing platform with the largest fleet and widest selection in North America.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today held its first ever FF EAI Robotics “Built in USA” Upstream & Downstream Business Partner Conference at its LA headquarters. FF made numerous announcements and Company updates, including presenting the three-phase execution roadmap for FF EAI Robotics’ “Built in USA” Acceleration Program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826459178/en/

Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027

Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027

Industry guests attending the event included Steven Newton, Senior Consultant of the U.S. General Services Administration and a member of the Los Angeles Unified School District Procurement Committee; Andrew Stokes, President of MOSO Robotics; and Praveen Penmetsa, Founder of Motivo Engineering. They spoke highly of FF’s established industry foundation, technological strength, and compliance capabilities in robotics, as well as the industry alliance initiative proposed by the Company.

A video recap of the conference can be viewed here:https://www.ff.com/us/built-in-usa/

FF officially begins recruiting downstream partners and unveils the FF PAR Revenue Flywheel, enabling the Company’s partners to earn not only one-time sales margins, but also recurring income that builds over time as the ecosystem grows, creating higher returns for our partners.

On September 28, FF will host Part Two of the FF EAI Robotics “Built in USA” Launch and Business Partner Conference. Together with our upstream partners, FF will work to build the industry ecosystem. FF’s “Built in USA” strategy will provide a compliant entry point for upstream partners looking to expand into the U.S. market, turning advanced global technologies, supply chains, and system capabilities into market opportunities in the United States.

Against the backdrop of the FCC’s new policy framework, FF, as the first U.S. Company to have delivered both humanoid and bionic robots, is positioned to capitalize on the market opportunities created by rising industry entry barriers and accelerate the conversion of its first-mover advantage in product delivery into a competitive market advantage.

FF has officially upgraded its EAI robotics strategy to the Four-Core Full-Stack AI Ecosystem Strategy, comprising the EAI Brain; EAI Devices; Industry Productivity Solutions and Developer Platform; and EAI Data Factory.

“Robotics companies fall into two types: EAI robotics companies and non-EAI robotics companies. What sets an EAI robot apart is a combination of critical capabilities, including an intelligent brain, foundation models, a physical embodiment, and the ability to generalize across different tasks and environments. EAI robotics companies tend to bring substantially greater value,” said YT Jia, Founder and Global CEO of Faraday Future. “Join us on this ‘Built in USA’ journey. Together, we can move the robotics industry forward and maximize value for every distributor partner who joins us.”

FF EAI Robotics’ “Built in USA” Strategy and FCC Compliance:

Built on FF’s “Four-Core Full-Stack AI” ecosystem, FF will build U.S.-based R&D, production, and supply chain capabilities for EAI Devices and key components in phases while complying with the latest FCC policies targeted towards robotics. At the same time, it will strengthen its U.S. capabilities across the EAI Brain, Industry Productivity Solutions and Developer Platform, and EAI Data Factory, targeting to establish itself as a leading EAI robotics platform company in the United States; and drive the rapid, long-term growth of the U.S. EAI robotics industry.

FF began executing this strategy last year, when it accelerated its EAI robotics business; core Phase One capabilities are now complete.

The new policies recently announced by the FCC are not intended to cut off global collaboration. Advanced technologies and supply chain capabilities from around the world can still be brought into the United States. For global partners, a compliant U.S. platform can still provide a more efficient path into the U.S. market. This is also where FF offers unique value.

FF has already established an evolutionary flywheel driven by its “Four-Core Full-Stack AI” ecosystem, its Global Industry Bridge, and scaled deliveries. Taken together, the new policies are reshaping the rules of the industry and, with full FCC compliance as a prerequisite, further strengthen the value of that bridge—positioning FF to translate its advantages in compliance, global connectivity, and early scaled delivery into market share and a stronger competitive moat.

Three-Phase Execution Roadmap for FF EAI Robotics’ “Built in USA” Acceleration Program:

In Phase One, by the end of July this year, FF had completed the initial implementation of three core capabilities: the EAI Brain, Industry Productivity Solutions and Developer Platform, and the EAI Data Factory. This laid the technical foundation for the continued development of its EAI Devices. On the manufacturing side, FF also began establishing its U.S. footprint, including evaluating a retrofit of the Company’s Hanford factory and possible sites for a new facility.

In Phase Two, from this August through the first quarter of 2027, FF will accelerate the “Assembled in USA” implementation for EAI Devices and the parts required for FCC compliance. FF’s goal is to bring its robotics factory online by the end of this year and have its first new EAI Device roll off the production line in February 2027.

In Phase Three, by the fourth quarter of 2028, FF’s ultimate goal is to achieve “Made in USA” for its EAI Devices, the parts required for FCC compliance, and a group of critical parts capable of driving major advances across the industry.

The above three-phase roadmap and timelines reflect the Company’s current targets and may be adjusted based on current FCC policies, applicable laws and regulations, and actual execution progress.

New EAI Devices selected for the “Built in USA” program:

The first two new EAI Devices selected for the “Built in USA” program are the full-size humanoid Next Futurist and the quadruped Next Aegis.

Next Futurist is an “All-in-One Professional Expert,” designed for high-value use cases including research and education, industrial applications, services, and inspection. Its key upgrades will focus on motion control, multimodal perception, and AI capabilities. We will also explore advanced technologies such as NVIDIA SONIC, enabling it to progress from motion execution toward task understanding and autonomous operation.

Next Aegis is positioned as an “All-Scenario EAI Quadruped Robot” for education, inspection, security, and other applications at scale. Its key upgrades will focus on power, endurance, complex-terrain mobility, and autonomous navigation. Its modular design will also allow it to be configured for different use cases. More importantly, both products will share the EAI Brain, Data Factory, Developer Platform, and Skills system. Together, they will validate the technical approach of “One Brain, Multiple Forms; Multiple Forms, Multiple Capabilities” and help keep the evolutionary flywheel of FF’s “Four-Core Full-Stack AI” ecosystem moving.

EAI Education Ecosystem Updates:

The Company has built the initial foundation of an education ecosystem, covering EAI Devices, structured curricula, AI development tools, hands-on robotics training, and teacher support. We have also designed a curriculum framework spanning nine levels and three stages of learning. The Company has established partnerships with two public school districts in California—Lynwood Unified and El Segundo Unified—covering approximately 22 K–12 schools. Our EAI robotics summer camps have validated the model in real educational settings. This has established B2B educational institutions and B2C family education entry points with an FF representative joining the El Segundo Unified School District’s CTE Advisory Committee.

FF has completed the initial development of Version 1.0 of FF’s Industry Productivity Solution for the EAI Education Ecosystem. It will officially launch on September 19. The solution will serve K–12 schools, after-school programs, and family education. It will empower our partners across eight dimensions, including EAI Devices, level-based curricula, development tools, teacher training, instructional management, and technical support.

FF has also officially launched its EAI EDU Nationwide Replication at Scale Sub-Campaign. Over the next four months, FF will expand its K–12 demonstration programs and advance blended learning, teacher training, and its classroom management platform. FF will also accelerate progress toward implementation for 11 potential education partnerships currently under development across 10 U.S. states.

Partnership Policy & Downstream Partner Recruitment:

FF officially launched its Partnership Policy & Downstream Partner Recruitment at today’s event. FF’s robotics business maintained ramp up in sales with shipments exceeding 400 units to date and a positive contribution margin throughout the first half of the year. At the same time, the Data Factory has completed its first commercial closed loop, and the Developer Platform is live.

FF is recruiting four types of partners—each able to create value within the commercial flywheel and share in the returns. Distributors partners—including distributors, regional agents, and rental operators, who bring market coverage and local service capabilities. Industry solution partners and developers who bring industry expertise and project delivery capabilities. AI partners, who contribute Skills modules and model capabilities. And data and Skills partners, who contribute compliant data and validated assets.

FF PAR partners can access two forms of value. Direct value includes product margins and business development incentives. These programs are supported by signed agreements and a fulfillment record. The flywheel value will be created after a robot enters a customer’s real-world environment. This includes deployment, training, operations, software subscriptions, curricula, upgrades, capacity expansion, and referrals. Each of these services is contracted, priced, and accepted independently. None of them constitutes a disguised discount on another.

RoboShare Updates:

RoboShare is AIxC’s robot-sharing and operations platform, and FF is AIxC’s majority stockholder. RoboShare aims to build an “Uber + Turo”-style sharing and operations platform for robots. Its goal is to unlock their value as shared assets—transforming them from hardware sold through a one-time transaction into a new type of productive asset capable of generating ongoing revenue. RoboShare has already completed its first paid commercial order and secured a one-year rental order valued at $33,000. This long-term demand led an education customer to expand its original plan to purchase five NAVI robots into a firm order for 23 FFAI robots, generating 18 additional unit sales for FFAI.

AIxC officially launched RoboShare & Co. across North America, offering five partnership models: ROBOPARs support customer development, robot sales, local fulfillment, and lease-to-own programs; asset owners list eligible robots; users access diverse robots with transportation, operation, and on-site services; referral partners introduce customer demand and earn bonuses under official policies; and rental operators provide local transportation, operation, maintenance, repair, and after-sales support. Building on its initial orders, RoboShare is expanding its partner network with the goal of becoming North America’s largest and most diverse robot-sharing platform.

RoboShare is moving beyond its initial orders and beginning to expand its partner network across North America. It aims to build North America’s largest and most diverse robot-sharing platform.

Next, RoboShare will begin rolling out its Ten-City Strategy, starting in Los Angeles. We will validate repeat demand, equipment utilization, and its operating model. FF will provide AIxC with strategic, product, and technology support. In turn, RoboShare will help drive sales through real-world usage.

“FF combines deep roots in the United States with its role as a global Embodied AI industry bridge, and today’s conference brought together many new ideas from the Company,” said YT Jia, FF Founder and Global CEO. “FF is extending an invitation to all potential partners around the world: Let’s bring the best technologies, products, and supply chain capabilities to the United States, create value here, Built in USA, Benefit the World.”

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a “Four-Core Full-Stack AI” ecosystem of EAI Brain, Device, Industry Productivity Solutions and Developer Platform, and Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding Faraday Future Intelligent Electric Inc.’s (the “Company’s”) “Bridge Strategy,” the Company’s growth strategy, fundraising activities and prospects, the development of markets in which the Company operates or seeks to operate, the production and delivery of the FF 91, the Faraday X (FX) brand, and future compliance with Nasdaq listing requirements, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These forward-looking statements speak only as of the date of this call, and the Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible debt investors to fund the Company; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s reliance on Chinese OEMs for all of its robotics products; the possibility of the federal government banning imports of Chinese robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended June 30, 2026; the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Automotive Manufacturing Manufacturing Retail Autonomous Driving/Vehicles Automotive EV/Electric Vehicles Software Artificial Intelligence Hardware Luxury Technology Alternative Vehicles/Fuels Other Manufacturing Robotics Other Education Engineering Primary/Secondary Education

MEDIA:

Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Photo
Photo
Faraday Future Announces Execution Roadmap for Its “Built in USA” Acceleration Program and Launches Distributor Recruitment; Targets to Bring Its Robot Factory Online by Year-End and First New EAI Device Product Off the Line in February 2027
Logo
Logo

Capstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million Remaining

Capstone Publishes Investor FAQ: 75% of Convertible Note Principal Retired, Approximately $1.72 Million Remaining

FAQ reports approximately 21.75 million shares outstanding and gives direct answers on dilution, corporate requirements and the path to operating cash flow funding

NEW YORK–(BUSINESS WIRE)–
Capstone Holding Corp. (NASDAQ: CAPS), a national, technology-enabled building products distribution platform, today published an investor FAQ answering the questions shareholders have asked most frequently about the Company’s capital structure. The FAQ reports that approximately 75% of the original convertible note principal has been retired, with approximately $1.72 million remaining outstanding as of August 25, 2026, and states the Company’s current share count of approximately 21.75 million shares.

The FAQ responds to questions submitted by shareholders following the Company’s August 17 invitation. It addresses the August reduction of the notes’ conversion price, the remaining note balances and maturities, potential dilution, the current share count and restricted shares, the equity line, the reverse stock split authorization, the remediation of the material weakness, and how the Company expects to fund its corporate requirements over time through operating cash flow and traditional credit. The full document is available at FAQ URL.

“We answered the questions shareholders asked, with current figures as of publication,” said Matthew Lipman, Chief Executive Officer of Capstone. “Approximately 75% of the convertible note principal has been retired, our operating businesses funded their own obligations in the first half, and we are focused on retiring the remaining balance, so the Company no longer depends on this financing structure.”

In the second quarter, Capstone delivered 67% year-over-year revenue growth and 92% gross profit growth, with positive Stone Business Adjusted EBITDA, and reaffirmed its full-year guidance in its August 12 earnings release.

Non-GAAP Financial Measures

Stone Business Adjusted EBITDA is a non-GAAP financial measure. It is not a measure of financial performance under GAAP and should not be considered an alternative to net income (loss) or any other performance measure derived in accordance with GAAP, and it may not be comparable to similarly titled measures used by other companies. A reconciliation to net loss, the most directly comparable GAAP measure, together with the definition of the measure, is included in the Company’s earnings release dated August 12, 2026.

About Capstone Holding Corp.

Capstone Holding Corp. (NASDAQ: CAPS) is a national, technology-enabled building products distribution platform optimizing supply chains across 38 U.S. states and Canada. Through its Instone operating platform and inventory portal, the Company aggregates and delivers proprietary stone veneer, hardscape materials, and modular masonry systems. Capstone’s model combines digital infrastructure, owned-inventory logistics, and disciplined acquisitions to drive scalable margin expansion and operating leverage across its growing platform.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events and performance, including guidance regarding revenue, gross profit, and Stone Business Adjusted EBITDA, the retirement or refinancing of the Company’s convertible notes, expected capital requirements, M&A strategy, use of capital, and operating outlook. Actual results may differ materially from those projected due to a range of factors, including but not limited to the Company’s liquidity and access to capital; its ability to comply with, or obtain waivers of, financial covenants; the refinancing or repayment of indebtedness as it matures; conditions that may raise substantial doubt about the Company’s ability to continue as a going concern; acquisition timing and integration; macroeconomic conditions; and other execution risks. Please review the Company’s filings with the SEC, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, for a full discussion of these and other risk factors. Capstone undertakes no obligation to revise forward-looking statements except as required by law.

Investor Contact

Investor Relations

Capstone Holding Corp.

[email protected]

www.capstoneholdingcorp.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Retail Manufacturing Finance Other Construction & Property Supply Chain Management Residential Building & Real Estate Commercial Building & Real Estate Professional Services Construction & Property Other Technology Software Other Manufacturing Data Management

MEDIA:

Logo
Logo

ISG Announces 2026 ISG Paragon Awards™ Asia Winners

ISG Announces 2026 ISG Paragon Awards™ Asia Winners

Program spotlights sourcing partnerships that leverage AI, technology and new operating models to drive business success

SINGAPORE–(BUSINESS WIRE)–
Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has announced the winners of the second annual ISG Paragon Awards™ Asia, which recognize excellence and innovation in sourcing and technology.

The following winners were selected by an independent, external judge and announced at a gala awards dinner at the Fullerton Bay Hotel, Singapore, on August 26, 2026:

Best-in-Class Excellence: Outstanding delivery by a technology or service provider

  • Tata Consultancy Services, with CapitaLand Shared Services Pte. Ltd.

Community and Social Excellence: Exceptional delivery and innovation creating meaningful impact in an Asian country’s communities and citizens

  • Avanade Asia Pte Ltd., with National Healthcare Group (NHG), Singapore

Innovation: Imagination and entrepreneurial spirit in helping organizations future-proof their businesses and better serve clients

  • Tata Consultancy Services, with Tamil Nadu Police (SCRB)

Transformation: The successful transformation of an organization or key business function

  • Tata Consultancy Services, with State Bank of India (SBI)

Partnership of the Year: A high-performing partnership that exemplifies best practices in driving exceptional business outcomes and economic growth

  • Avanade, Inland Revenue Authority of Singapore, Microsoft and Accenture

In addition, HCLTech and Prudential Health India were recognized with Distinction for AI Excellence, for their forward-thinking application of AI, which showcases the transformative potential of technology to drive meaningful outcomes.

“Congratulations to the winners of the 2026 ISG Paragon Awards program for Asia,” said Michael Gale, partner and regional leader, ISG Asia Pacific. “These organizations are demonstrating the power of bold ideas, strong collaboration and disciplined execution. With responsible AI and new business models, this year’s winners are turning technology innovation into meaningful benefits for communities and measurable, lasting business impact.”

The ISG Paragon Awards were established in 2010 in the Australia/New Zealand region, and have since expanded to cover North America, Europe, Asia and South America. Full details are available here.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Press Contacts:


Laura Hupprich, ISG

+1 203-517-3132

[email protected]

Erik Arvidson, Matter Communications for ISG

+1 978-518-4542

[email protected]

KEYWORDS: Singapore Southeast Asia Asia Pacific

INDUSTRY KEYWORDS: Software Networks Data Analytics Consulting Artificial Intelligence Data Management Professional Services Technology

MEDIA:

Logo
Logo

Mesoblast Reports Substantial Revenue Growth to US$120M


RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment


Financial Results and Operational Update for Full Year Ended June 30, 2026

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026).

Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026. The financial result is a product of continued growth in RYONCIL market adoption and focus on disciplined capital allocation while investing in our high-value opportunities.

We plan to expand RYONCIL use to adults with severe steroid-refractory acute graft versus host disease (SR-aGvHD) as both a third-line treatment and as part of second-line treatment regimen together with ruxolitinib, a market three times larger than the pediatric market.

Most exciting is the completion of patient treatment in the Phase 3 trial of rexlemestrocel-L in the blockbuster chronic low back pain indication which will readout next year. A successful outcome positions for a potential multi-billion-dollar market opportunity.”

FINANCIAL HIGHLIGHTS FOR FY2026

1

Ryoncil

®

cash generation funding significant pipeline opportunities

  • Total revenue of US$120.3 million up from US$17.2 million in the prior year period.
  • Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) generated net revenue of US$115.2 million after gross to net adjustment of 13.4%.
  • Reported gross profit was US$103.6 million.
  • Gross profit excluding amortization was US$109.7 million versus US$16.0 million in the prior year period.
  • During the period research & development expense increased by US$39.7 million, after adjusting for the inventory benefit of $23.0 million in the previous period. This investment in R&D comprised product development for both remestemcel-L and rexlemestrocel-L platforms, phase 3 clinical trials, and regulatory filing activities.
  • Reported net loss for the period was reduced by 44% or US$44.6 million to US$57.5 million compared to US$102.1 million in the prior year period. Reported net loss in the second half was US$17.3 million, a 68% reduction on the prior comparative period.
  • Net operating cash spend of US$43.8 million, with spend of US$13.4 million for the second half. This compares with US$50.0 million in the prior year period.
  • Period-end cash balance of US$103 million. During the period Mesoblast entered into a US$125.0 million five-year non-dilutive credit-line facility, consolidating and retiring two higher cost facilities.

OPERATIONAL HIGHLIGHTS FOR FY2026

Ryoncil

®

commercial execution: first full year of product launch

  • Successfully launched RYONCIL in the United States for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD), establishing Mesoblast as a fully integrated commercial-stage biotechnology company.
  • Secured broad institutional adoption at leading pediatric transplant centers across the U.S. onboarding more than 50 sites since launch, including 14 of the 15 largest sites that account for nearly half of pediatric transplant volumes.
  • Expanded payer coverage and reimbursement access to over 280 million covered lives across commercial and government payors, supporting increased patient treatment and facilitating market penetration.
  • Marked reduction in median time from patient identification to initiated treatment from 29 days at launch to 8 days.
  • We have honed commercial, medical affairs, market access, patient services and distribution infrastructure to support long-term revenue growth.

RYONCIL label expansion for adults with severe SR-aGvHD and children with Duchenne

  • The Company is executing on its strategy to extend its FDA-approved label for its flagship product RYONCIL beyond children to adults with SR-aGvHD.
  • Strategically Mesoblast is positioning RYONCIL as both third-line treatment in adults with SR-aGvHD who have failed ruxolitinib or other second-line agents and as part of second-line treatment regimen together with ruxolitinib in adults with Grade III/IV SR-aGvHD, a market three times larger than the pediatric market.
  • In February 2026 the Company presented data at the Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Blood and Marrow Transplant Research (CIBMTR) showing 76% Day 100 survival in adolescents and adults treated with RYONCIL for third-line SR-aGvHD after failure of ruxlolitinib or other agents.2 These patients have historically had survival rates of 20 to 30%.3
  • The registration trial for label extension of RYONCIL into adults with SR-aGvHD as part of a second-line regimen with ruxolitinib has commenced and is currently enrolling patients, with up to 40 sites across the U.S. expected to be activated this year representing approximately 60% of the ~8,500 annual U.S. allogeneic adult bone marrow transplant population.
  • Mesoblast received Investigational New Drug (IND) clearance from U.S. Food and Drug Administration (FDA) to proceed directly to a registrational trial evaluating RYONCIL in ambulatory children aged 5-9 years with Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.

Major milestones achieved for rexlemestrocel-L

  • Completed 350 patients treated in the pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with inflammatory degenerative disc disease.
  • This milestone was achieved after strong demand from trial investigators to increase patients enrolled in this innovative program from 300 to 350.
  • The trial’s primary endpoint aims to confirm the durable pain reduction at 12 months from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial. With 350 treated patients, the trial is well-powered for showing a greater treatment benefit in patients receiving rexlemestrocel-L compared with controls. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-CY2027 after the last treated patient has completed 12 months follow-up.
  • CLBP caused by inflammation and degenerative disc disease is a serious condition with a prevalence of over 7 million people in the U.S. alone. The indication has total addressable market of >US$10 billion.
    • Received a Biologics License Application (BLA) filing number from FDA and requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). The request for modular review will be discussed with the Agency next quarter.

Next generation technologies

  • At our R&D Day in April we unveiled programs that are focused on expanding and diversifying the pipeline by developing products emanating from two next generation technology platforms: chimeric antigen receptor modified mesenchymal stromal cells (CAR-MSC) and oncolytic virus loaded mesenchymal stromal cells (OV-MSC).
  • Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast’s products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration
  • The foundational work on the CAR technology was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering.4 The investigators identified various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases. This provides Mesoblast with an immediate opportunity to generate products with even greater potency for ulcerative colitis, Crohn’s disease, or Lupus Nephritis.
  • Mesoblast is developing oncologic therapies based on its mesenchymal lineage stromal cells delivering highly potent oncolytic viruses systemically to a wide range of tumors. Mesenchymal lineage stromal cells can cloak the oncolytic viruses from rapid elimination by the immune system and can deliver them in a targeted manner to the sites of distant primary and metastatic tumors via the cells’ tumor homing properties.
  • To develop therapeutic cell-oncolytic virus combination products, Mesoblast has exclusively licensed a best-in-class oncolytic virus technology platform from Baylor College of Medicine (BCM).
  • Combined, these activities strengthen the Company’s position as a global leader in allogeneic cellular medicines through execution across regulatory, commercial and development objectives.

Conference Call

There will be a webcast today, beginning at 6.30pm EDT (Wednesday, August 26); 8.30am AEST (Thursday, August 27). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/

The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com

Other

Please refer ‘Risk Factors’ and ‘Management’s Discussion and Analysis’ sections in our Form 20F filed with SEC and Appendix 4E filed with ASX.

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,100 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

References / Footnotes

  1. See summary consolidated financial tables at the end of this release.
  2. Kurtzberg J, et al. Remestemcel-L-rknd (Ryoncil) Improves Survival After Failure of Second-Line Treatment for SR-aGVHD [Poster presentation]. 2026 Transplantation & Cellular Therapy Tandem Meetings
  3. Jagasia M et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749
  4. Sirpilla, O. et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat Biomed Eng. 2024 April; 8(4): 443–460.

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Not financial product advice

This announcement does not constitute financial product advice or investment advice (nor tax, accounting or legal advice) and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate professional advice.

Disclaimer

To the maximum extent permitted by law, Mesoblast and its directors, officers, employees, advisers and agents disclaim any obligation or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions, and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, any liability for negligence).

Release authorized by the Chief Executive.

For more information, please contact:


Corporate Communications / Investors
 
Paul Hughes  
T: +61 3 9639 6036  
   

Media – Global

Media – Australia
Rubenstein BlueDot Media
Caroline Nelson Steve Dabkowski
T: +1 703 489 3037 T: +61 419 880 486
E: [email protected] E: [email protected]

Consolidated Income Statement

  Year Ended June 30,
(in U.S. dollars, in thousands, except per share amount) 2026
  2025
Revenue:      
Product sales, net 115,153     11,263  
Royalty revenue 5,097     5,935  
Total revenues 120,250     17,198  
Cost of revenues (including amortization of currently marketed intangible assets, 2026: $6,126: 2025: $3,937) (16,667 )   (5,130 )
Research & development (97,509 )   (34,807 )
Selling, general and administration (57,346 )   (39,309 )
Fair value remeasurement of contingent consideration 12,057     (14,887 )
Fair value remeasurement of warrant liability 859     (4,962 )
Other operating income and expenses 5,308     3,053  
Finance costs (23,839 )   (22,968 )
Loss before income tax (56,887 )   (101,812 )
Income tax (expense)/benefit (613 )   (330 )
Loss attributable to the owners of Mesoblast Limited (57,500 )   (102,142 )
       
Losses per share from continuing operations attributable to the ordinary equity holders of the Group: Cents   Cents
Basic – losses per share (4.44 )   (8.46 )
Diluted – losses per share (4.44 )   (8.46 )

Consolidated Statement of Comprehensive Income

  Year Ended June 30,
(in U.S. dollars, in thousands) 2026
  2025
Loss for the period (57,500 )   (102,142 )
Other comprehensive (loss)/income      
Items that may be reclassified to profit and loss      
Exchange differences on translation of foreign operations 259     1,160  
Items that will not be reclassified to profit and loss      
Financial assets at fair value through other comprehensive income (1,388 )   374  
Other comprehensive (loss)/income for the period, net of tax (1,129 )   1,534  
Total comprehensive losses attributable to the owners of Mesoblast Limited (58,629 )   (100,608 )

Consolidated Balance Sheet

As of June 30,
(in U.S. dollars, in thousands) 2026
  2025
Assets      
Current Assets      
Cash & cash equivalents 102,914     161,551  
Trade & other receivables 57,660     14,866  
Prepayments 8,806     5,687  
Inventory 28,111     22,246  
Total Current Assets 197,491     204,350  
       
Non-Current Assets      
Property, plant and equipment 1,818     1,702  
Right-of-use assets 6,196     4,121  
Financial assets at fair value through other comprehensive income     1,388  
Other non-current assets 1,204     1,296  
Intangible assets 566,370     571,826  
Total Non-Current Assets 575,588     580,333  
Total Assets 773,079     784,683  
       
Liabilities      
Current Liabilities      
Trade and other payables 46,806     19,082  
Provisions and other liabilities 11,766     20,985  
Borrowings 10,597     54,155  
Lease liabilities 3,031     2,680  
Warrant liability 8,912     5,724  
Total Current Liabilities 81,112     102,626  
       
Non-Current Liabilities      
Provisions and other liabilities 7,356     10,793  
Borrowings 108,638     67,739  
Lease liabilities 5,068     3,583  
Deferred consideration 2,500     2,500  
Total Non-Current Liabilities 123,562     84,615  
Total Liabilities 204,674     187,241  
Net Assets 568,405     597,442  
       
Equity      
Issued Capital 1,530,774     1,508,846  
Reserves 106,034     99,499  
Accumulated losses (1,068,403 )   (1,010,903 )
Total Equity 568,405     597,442  

Consolidated Statement of Cash Flow

  Year Ended June 30,
(in U.S. dollars, in thousands) 2026
  2025
Cash flows from operating activities      
Receipts from customers 88,447     5,704  
Government grants and tax incentives and credits received 22     905  
Payments to suppliers and employees (inclusive of goods and services tax) (136,210 )   (60,110 )
Interest received 3,910     3,549  
Income taxes received/(paid) 1     (2 )
Net cash (outflows) in operating activities (43,830 )   (49,954 )
       
Cash flows from investing activities      
Payments for property, plant and equipment (833 )   (680 )
(Payments for)/Receipt from investment in sublease (125 )   241  
Receipt of security deposits     609  
Payments for licenses (65 )   (50 )
Net cash (outflows)/inflows in investing activities (1,023 )   120  
       
Cash flows from financing activities      
Proceeds from borrowings 121,039      
Repayment of borrowings (124,981 )   (7,824 )
Payment of transaction costs from borrowings (5,358 )   (1,348 )
Interest and other costs of finance paid (17,756 )   (5,266 )
Proceeds from issue of shares 2,602     161,205  
Proceeds from exercise of options 7,681     5,177  
Proceeds from issue of warrants 3,961     1,647  
Payments for share issue costs (523 )   (4,314 )
Payments for lease liabilities (2,308 )   (1,941 )
Proceeds from settlement of lease liabilities 314      
Net cash (outflows)/inflows by financing activities (15,329 )   147,336  
       
Net (decrease)/increase in cash and cash equivalents (60,182 )   97,502  
Cash and cash equivalents at beginning of period 161,551     62,960  
Foreign exchange gains/(losses) on the translation of foreign bank accounts 1,545     1,089  
Cash and cash equivalents at end of period 102,914     161,551  



Standard Nuclear Reports Second Quarter and Year-to-Date 2026 Results

Standard Nuclear Reports Second Quarter and Year-to-Date 2026 Results

Total Contract Backlog Grows Six-Fold Since March 31 to $576.9 Million as Qualified Pipeline Converts to Long-Term Contracts

  • Generated $4.7 million of revenue in the second quarter, an approximately eight-fold increase from $0.6 million in the prior-year period

  • Delivered 50 kgU of TRISO fuel in the second quarter and the balance of the reactor core subsequent to quarter end, completing the first reactor core of commercially produced TRISO fuel supplied by an independent U.S. manufacturer

  • Total Contract Backlog* of $241.5 million at June 30, 2026, up from $91.3 million at March 31, 2026, with Funded Backlog increasing to $61.9 million from $8.2 million

  • Subsequent to quarter end, executed a fuel supply agreement for a firm commitment of one MTU of HALEU TRISO fuel, plus a customer option for up to seven additional MTU. Funded Backlog increased approximately 93% to $119.3 million and Total Contract Backlog to $576.9 million.

  • Construction substantially completed at the new Tennessee (“SN-TN”) and new Idaho (“SN-ID”) production facilities, with start-up, commissioning and authorization activities underway and authorization to operate targeted for the fourth quarter of 2026

  • Subsequent to quarter end, completed initial public offering on the New York Stock Exchange, adding approximately $137.7 million of net proceeds and ending the period with a debt-free balance sheet of approximately $239.9 million of cash on a pro forma basis

  • Selected by the U.S. Department of Energy (the “Department” or “DOE”) for advanced contract negotiations under the Surplus Plutonium Utilization Program

*See Key Operating Metric definitions below

OAK RIDGE, Tenn.–(BUSINESS WIRE)–
Standard Nuclear, Inc. (NYSE: STDN) (“Standard Nuclear” or the “Company”), a reactor-agnostic producer of TRISO nuclear fuel, today reported financial results for the three and six months ended June 30, 2026. This release represents the Company’s first quarterly earnings report as a public company following the completion of its initial public offering on July 17, 2026.

“Advanced nuclear energy deployment is accelerating following a series of successful reactor startups this summer, but growth will rely on industrial-scale fuel supply,” said Kurt Terrani, President and Chief Executive Officer of Standard Nuclear. “Standard Nuclear is currently the only independent U.S. company producing TRISO fuel at scale for commercial customers across diverse applications. In the second quarter we made our first commercial delivery and we completed our first reactor core shortly after quarter end. We are also expanding capacity as construction at our new Tennessee and Idaho facilities is substantially complete. And a newly signed fuel supply agreement has effectively doubled our Funded Backlog.”

Key Operating Metrics

Total Contract Backlog represents the sum of Funded Backlog, Purchase Options under Executed Contracts and Unfunded Backlog. Because it includes unexercised customer options and non-binding arrangements, Total Contract Backlog is not a measure of contracted revenue and should not be relied upon as an indicator of future results.

Funded Backlog represents contracted fuel sales under binding commitments or agreements with firm delivery obligations, providing direct visibility into near-term revenue. Funded Backlog is presented net of revenue recognized and is reduced as the Company performs and delivers under its contracts.

Purchase Options under Executed Contracts represents contractually granted but unexercised customer options. Exercise is at the sole discretion of the customer, and these amounts are not reflected in the Company’s financial statements until exercised.

Unfunded Backlog represents the dollar value of intended fuel sales under memoranda of understanding, non-binding framework agreements or non-binding term sheets, and letters of intent. Certain Unfunded Backlog is associated with Fuel Development Agreements that include nominal deposits to reserve production queue position.

Qualified Pipeline represents vetted potential sales opportunities not yet subject to executed agreements. These represent non-binding indications of interest and remain subject to negotiation of commercial terms and other conditions. Qualified Pipeline is not included in Total Contract Backlog.

Backlog is difficult to determine accurately, companies in the Company’s industry may define it differently, and in the event of a cancellation or scope adjustment the Company typically has no contractual right to the revenues reflected. Backlog at any point in time may not accurately represent expected revenue and should not be relied upon as a stand-alone indicator of future results.

Converting pipeline into contracted demand

The following table summarizes Total Contract Backlog and Qualified Pipeline:

($ in millions)

 

March 31,

2026

 

June 30,

2026

 

August 26,

2026

 

 

 

 

 

 

 

Funded Backlog

 

$

8.2

 

$

61.9

 

$

119.3

Purchase Options under Executed Contracts

 

 

0.0

 

 

156.5

 

 

443.5

Unfunded Backlog

 

 

83.1

 

 

23.1

 

 

14.1

Total Contract Backlog

 

$

91.3

 

$

241.5

 

$

576.9

Qualified Pipeline

 

 

573.0

 

 

986.3

 

 

696.3

Total Contract Backlog and Qualified Pipeline

 

$

664.3

 

$

1,227.8

 

$

1,273.2

Total Contract Backlog grew to $241.5 million at June 30, 2026 from $91.3 million at March 31, 2026, and to $576.9 million giving effect to the August 2026 fuel supply agreement. Over the same period, Funded Backlog grew from $8.2 million to $61.9 million and, giving effect to the August 2026 fuel supply agreement, to $119.3 million.

Unfunded Backlog declined from $83.1 million at March 31, 2026 to $23.1 million at June 30, 2026 as non-binding arrangements were executed as binding commitments, and to $14.1 million giving effect to the August 2026 fuel supply agreement.

Growth in the second quarter and subsequent to quarter end reflects the conversion of previously disclosed Qualified Pipeline opportunities and non-binding arrangements into executed contracts. The Company continues to pursue a Qualified Pipeline of prospective fuel orders under negotiation, directly, and through its joint venture with Framatome.

Separately, the Company’s Qualified Pipeline of prospective fuel orders in active discussion was approximately $696.3 million as of August 26, 2026, compared to approximately $986.3 million as of June 30, 2026. The decrease reflects the conversion of pipeline opportunities into executed contracts rather than a reduction in prospective demand. Total Contract Backlog and Qualified Pipeline together represent approximately $1.3 billion against the Company’s estimated serviceable addressable market of $3.2 billion through 2030.

First commercial reactor core completed

During the second quarter, Standard Nuclear made its first commercial delivery of TRISO fuel, delivering 50 kgU to Radiant Industries for its Kaleidos microreactor. The fuel is now at the Department’s Demonstration of Microreactor Experiments (“DOME”) facility at Idaho National Laboratory. The Company delivered the remainder after quarter end, completing delivery of a full core load of TRISO fuel for Radiant’s Kaleidos microreactor, which is a transportable high-temperature gas-cooled microreactor fueled by HALEU TRISO in prismatic graphite blocks. This is the first complete reactor core of commercially produced TRISO fuel supplied by an independent U.S. manufacturer. Radiant has stated that the Department awarded it exclusive access to the DOME test bed for a full year following a competitive selection process, where the core will support a full-power, full-temperature demonstration. Radiant has also stated that the campaign uses the same reactor design and the same fuel specification intended for its customer deployments, meaning the fuel delivered in the second quarter was produced to the Company’s commercial production specification rather than to a test-article specification.

Tennessee and Idaho facilities

Construction is substantially complete at SN-TN in Oak Ridge, Tennessee and SN-ID in Idaho, two identical facilities, each starting at up to one MTU per year and designed to scale to 2.5 MTU each, for a combined capacity of up to five MTU per year. The Department has approved the Preliminary Documented Safety Analysis for both facilities. Manufacturing module commissioning and remaining authorization activities are underway, including preparation of the Documented Safety Analysis for each site and a subsequent readiness review. Once fully authorized, both facilities are intended to operate as Hazard Category 2 nuclear facilities.

The Company’s operating SN-0 facility in Oak Ridge continues to produce TRISO fuel with capacity of up to 0.5 MTU annually. The Company currently targets authorization to operate at both SN-TN and SN-ID in the fourth quarter of 2026.

The following table summarizes the licensing status of the Company’s production facilities:

Project

Licensor

Licensee

License Pathway

License Status

Target Approval

SN-0

DOE

SN

10CFR830

Operational

SN-TN

DOE

SN

10CFR830

In progress

Q4 2026

SN-ID

DOE

SN

10CFR830

In progress

Q4 2026

SN-F

NRC

Framatome

10CFR70 (LAR)

Approved

Surplus Plutonium Utilization Program

During the second quarter, Standard Nuclear was selected by the Department for advanced contract negotiations under the Surplus Plutonium Utilization Program. The program makes designated surplus plutonium available to industry for conversion into advanced reactor fuel. Standard Nuclear is the only participant without a proprietary reactor program and expects to fabricate plutonium-based TRISO as an independent supplier to any advanced reactor developer using the material. Selection is for negotiation and does not constitute a contract award.

Framatome joint venture regulatory milestone

In June 2026, the U.S. Nuclear Regulatory Commission approved a license amendment request for Framatome’s Richland, Washington fuel manufacturing facility, raising the site’s licensed uranium enrichment limit from 6.5 weight percent to just under 10 weight percent of U-235 and authorizing both the conversion of uranium hexafluoride to uranium oxide powder and the fabrication of TRISO fuel particles. The approval clears the regulatory path for the Company’s joint venture with Framatome to begin production of TRISO-based fuels at the site in 2027, with initial capacity expected of approximately one MTU of TRISO fuel annually and ability to expand to two MTU, representing capacity incremental to the Company’s wholly-owned production facilities.

Backlog

Total Contract Backlog was $241.5 million as of June 30, 2026, consisting of $61.9 million of Funded Backlog, $156.5 million of Purchase Options under Executed Contracts and $23.1 million of Unfunded Backlog. This compares to Total Contract Backlog of $91.3 million as of March 31, 2026, consisting of $8.2 million of Funded Backlog, no Purchase Options under Executed Contracts and $83.1 million of Unfunded Backlog.

In August 2026, the Company entered into a definitive multi-metric ton fuel supply agreement with Radiant Industries, Inc., converting into definitive form a binding term sheet executed in May 2026, as amended. Because the binding term sheet was executed during the second quarter, the firm commitment and optional amounts were already reflected in Funded Backlog and Purchase Options under Executed Contracts as of June 30, 2026, and execution of the definitive agreement did not increase Total Contract Backlog. Radiant has stated that each Kaleidos unit operates for up to five years before refueling across a twenty-year operating life, so each initial core delivered under a fuel supply agreement is expected to be followed by recurring refueling requirements over the operating life of the unit.

In August 2026, subsequent to quarter end, the Company entered into a fuel supply agreement with Antares Nuclear, Inc. providing for a firm commitment of one MTU of HALEU TRISO fuel and a customer option for up to an additional seven MTU over the next several years. The firm commitment increased Funded Backlog approximately 93% to $119.3 million, and the option increased Purchase Options under Executed Contracts to $443.5 million. Unfunded Backlog decreased to $14.1 million from $23.1 million at June 30, 2026, reflecting the conversion of a previously non-binding arrangement into the executed agreement. Giving effect to the agreement, Total Contract Backlog is $576.9 million.

“What this quarter demonstrates is conversion,” said Kevin Harrill, Chief Financial Officer of Standard Nuclear. “Total Contract Backlog grew to $241.5 million at June 30 from $91.3 million at March 31, and to $576.9 million giving effect to the August 2026 fuel supply agreement. Funded Backlog, the portion under binding commitment, grew from $8.2 million to $119.3 million over that period, now predominantly under fuel sales agreements rather than development work. We entered the third quarter with $102.2 million of cash, which had already fully funded construction and commissioning of our Tennessee and Idaho facilities. The July IPO added approximately $137.7 million of net proceeds and was opportunistic. We accessed the public markets from a position of strength, at a moment when demand for a secure domestic nuclear fuel supply chain has never been greater. With roughly $239.9 million of pro forma cash on a debt-free balance sheet and Total Contract Backlog of $576.9 million, we have the flexibility to move faster than our existing plan: adding capacity ahead of demand, deepening our supply chain, and converting backlog into recurring production revenue as we look to bring our facilities online.”

Initial Public Offering

On July 15, 2026, the Company priced its initial public offering of 10.0 million shares of Class A common stock at a public offering price of $15.00 per share. The Company’s Class A common stock began trading on the New York Stock Exchange under the symbol “STDN” on July 16, 2026, and the offering closed on July 17, 2026, resulting in net proceeds to the Company of approximately $137.7 million, after deducting underwriting discounts, commissions, and offering expenses.

Financial Results

Amounts presented in this section are rounded to the nearest $0.1 million. Individual components may not sum to totals due to rounding.

Comparison of Three Months Ended June 30, 2026 to Three Months Ended June 30, 2025

Revenue increased to $4.7 million for the three months ended June 30, 2026, compared to $0.6 million for the three months ended June 30, 2025. The $4.1 million increase in revenue primarily reflects $3.1 million of product revenue related to deliveries of TRISO under one fuel supply agreement including the Company’s first commercial delivery and an increase in work performed under fuel development contracts and research and development projects performed for U.S. government agencies.

Cost of revenue increased to $1.6 million for the three months ended June 30, 2026, compared to $1.2 million for the three months ended June 30, 2025. The increase reflects the scale-up of production operations at SN-0 as the Company qualified processes and manufactured its first commercial core. The $0.4 million increase comprised a number of individually smaller items, the largest of which was an increase in share-based compensation expense.

Gross profit was $3.2 million for the three months ended June 30, 2026, compared to a gross loss of $0.6 million for the three months ended June 30, 2025. This marked the Company’s first quarter of gross profit, reflecting its first commercial product deliveries.

General and administrative costs increased to $5.5 million for the three months ended June 30, 2026, compared to $1.0 million for the three months ended June 30, 2025. The $4.5 million increase was primarily attributable to a $1.6 million increase in share-based compensation expense, a $1.5 million increase in third-party consulting fees related to the Company’s transition to a public company, and a $1.4 million increase in payroll and related benefit costs. These increases reflect the build-out of the internal infrastructure required to operate as a public company, including the addition of finance, accounting, legal and compliance capability, incurred in advance of scalable commercial deployment.

Research and development expenses were $2.0 million for the three months ended June 30, 2026, compared to no research and development expenses for the three months ended June 30, 2025. The expenses consist of internal labor and process engineering work to establish and qualify the manufacturing processes required to bring SN-TN and SN-ID into commercial production, including preparation of the facilities’ licensing and authorization deliverables required under the Company’s Other Transaction Agreement with the Department of Energy. This work supported the Department’s approval of the Preliminary Documented Safety Analysis for both facilities and the commencement of Final Documented Safety Analysis preparation at each site, ahead of the Department’s readiness review. This investment underpins the Company’s replicable facility model, which is designed to bring a standard production facility online in approximately 11 months and expected to reduce the time and cost of each subsequent increment of capacity.

Loss from operations was $4.3 million for the three months ended June 30, 2026, compared to $1.6 million for the three months ended June 30, 2025. The $2.7 million increase reflects $6.5 million of incremental general and administrative costs and research and development expenses, consisting of the public company infrastructure build-out and the process qualification work required to authorize SN-TN and SN-ID, and a $0.4 million increase in cost of revenue, partially offset by a $4.1 million increase in revenue. This spending was incurred ahead of the production revenue the two new facilities are expected to generate upon receipt of an authorization to operate.

Net loss was $3.4 million, or $(0.12) per share, for the three months ended June 30, 2026, compared to $1.6 million, or $(0.06) per share, for the three months ended June 30, 2025, an increase of $1.8 million. The increase reflects a $4.5 million increase in general and administrative costs, $2.0 million of research and development expenses and a $0.4 million increase in cost of revenue, partially offset by a $4.1 million increase in revenue and a $0.9 million favorable change in other income, net. Net loss decreased sequentially to $3.4 million in the second quarter of 2026 from $7.7 million in the first quarter of 2026, primarily reflecting the Company’s first commercial product revenue.

Per share amounts are based on weighted average shares outstanding of 28,001,802 for the three months ended June 30, 2026, which reflect the Company’s pre-IPO capital structure. In connection with the initial public offering, all outstanding shares of preferred stock converted into common stock, and the Company issued 10.0 million shares of Class A common stock in the offering. As a result, approximately 154.2 million shares of common stock were outstanding following the offering. Per share amounts for periods presented are therefore not comparable to periods following the offering.

Comparison of Six Months Ended June 30, 2026 to Six Months Ended June 30, 2025

Revenue increased to $5.3 million for the six months ended June 30, 2026, compared to $0.9 million for the six months ended June 30, 2025. The $4.4 million increase in revenue was related to product revenue related to deliveries of TRISO under one fuel supply agreement including the Company’s first commercial delivery, as well as increased work on customer fuel development contracts and projects performed for U.S. government agencies.

Cost of revenue increased to $6.6 million for the six months ended June 30, 2026, compared to $2.3 million for the six months ended June 30, 2025. The increase in cost of revenue was driven by growth in the Company’s business operations reflecting the scale-up of production operations as the Company qualified processes and manufactured its first commercial core. The $4.3 million increase was primarily attributable to a $2.1 million increase in production supplies and facility-related costs, a $0.7 million increase in payroll and related benefit costs, a $0.9 million increase in share-based compensation expense, and a $0.6 million increase in engineering and related consulting fees.

Gross loss was $1.2 million for the six months ended June 30, 2026, compared to a gross loss of $1.4 million for the six months ended June 30, 2025. Gross loss for the six months ended June 30, 2026 includes first quarter costs for process qualification and production scale-up, without corresponding commercial product deliveries.

General and administrative costs increased to $9.4 million for the six months ended June 30, 2026, compared to $1.6 million for the six months ended June 30, 2025. The $7.8 million increase was primarily attributable to a $2.6 million increase in share-based compensation expense, a $2.6 million increase in third-party consulting fees related to the Company’s transition to a public company, a $2.0 million increase in payroll and related employee benefit costs, and a $0.6 million increase in other costs, including franchise and other taxes, marketing, information technology, travel, investor relations and business development. These increases reflect the build-out of the internal infrastructure required to operate as a public company across the finance, accounting, legal and compliance functions, incurred in advance of scalable commercial deployment.

Research and development expenses were $2.0 million for the six months ended June 30, 2026, compared to no research and development expenses for the six months ended June 30, 2025. The expense reflects investment in establishing and qualifying the manufacturing processes required to bring SN-TN and SN-ID into commercial production, including internal labor incurred in preparing the facility licensing and authorization deliverables required under the Company’s Other Transaction Agreement with the Department. This investment underpins the Company’s replicable facility model, which is designed to bring a standard production facility online in approximately 11 months.

Loss from operations was $12.5 million for the six months ended June 30, 2026, compared to $3.1 million for the six months ended June 30, 2025. The $9.4 million increase was primarily attributable to a $7.8 million increase in general and administrative costs, $2.0 million of research and development expenses and a $4.3 million increase in cost of revenue, partially offset by a $4.4 million increase in revenue. These costs reflect the scale-up of production operations at SN-0 in support of the Company’s first commercial deliveries, the process qualification work required to authorize SN-TN and SN-ID, and the build-out of public company infrastructure, each incurred ahead of the production revenue the Company’s new facilities are expected to generate.

Net loss was $11.1 million, or $(0.40) per share, for the six months ended June 30, 2026, compared to $9.9 million, or $(0.35) per share, for the six months ended June 30, 2025, an increase of $1.2 million. The increase in net loss reflects a $9.4 million increase in loss from operations, driven by higher cost of revenue, general and administrative costs, and research and development expenses, substantially offset by an $8.3 million favorable change in other income (expense), net attributable to non-operating charges recognized in the prior-year period that did not recur.

Per share amounts are based on weighted average shares outstanding of 28,000,906 for the six months ended June 30, 2026, which reflect the Company’s pre-IPO capital structure and are not comparable to periods following the initial public offering, after which approximately 154.2 million shares of common stock were outstanding.

Conference Call and Webcast

The Company will host a conference call to discuss these results on August 27, 2026 at 8:30 a.m. Eastern Time. The conference call will be webcast live and may be accessed in the Investor Relations section of the Company’s website at https://ir.standardnuclear.com. Investors and analysts may also register in advance at https://standard-nuclear-q2-2026-earnings-call.open-exchange.net/registration, and upon registering will receive a confirmation email with instructions for joining. The webcast will be in listen-only format followed by a live Q&A. A webcast replay will be available through Thursday, September 3, 2026.

Investor Presentation

The Company will post an investor presentation providing an overview of its business, technology and strategy to the Investor Relations section of its website at https://ir.standardnuclear.com. The Company intends to use its website as a means of disclosing material information and complying with its disclosure obligations under Regulation FD.

About Standard Nuclear

Standard Nuclear’s mission is to reliably deliver the essential building blocks of nuclear power at scale — enabling cost-effective, safe, and secure energy for the world. Standard Nuclear is focused on the large-scale production of advanced nuclear fuel and radioisotope power systems. It is the nation’s only independent manufacturer of TRISO fuel — a robust, high-performance fuel essential to advanced nuclear reactors for terrestrial, national security, and space applications. Standard Nuclear offers a reactor-agnostic supply of advanced fuels to the next-generation nuclear industry and delivers dependable radioisotope power solutions to the space and defense sectors. Through these efforts, it is helping to eliminate U.S. reliance on geopolitical adversaries for these strategically vital technologies. For more information, visit: https://www.standardnuclear.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which in this context means statements that express Standard Nuclear’s opinions, expectations, objectives, beliefs, plans, intentions, strategies, assumptions, forecasts or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” The words “may,” “will,” “could,” “should,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “continue,” “might,” “possible,” “potential,” “predict,” “project,” “goal,” “would,” “commit,” or, in each case, their negative or other variations or comparable terminology, and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which Standard Nuclear operates. Such forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties.

As a result of a number of known and unknown risks and uncertainties, the actual results or performance of Standard Nuclear may be materially different from those expressed or implied by these forward-looking statements. The following important risk factors could affect Standard Nuclear’s future results and cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements: risks related to our reliance on the commercialization timelines of advanced reactor developers; risks related to the fact that we are an early stage company with limited operating history; risks relating to our inability to achieve or sustain profitability; our backlog and our qualified pipeline of carefully vetted sales opportunities may not be realized or may not result in profits; risks related to financial and other difficulties experienced by our customers and suppliers that delay our operational plans; risks relating to our dependence on public support for nuclear power and continued demand for it; risks relating to the reduction in demand from data centers and artificial intelligence applications; risks related to cost increases and delivery delays due to our suppliers or customer’s fuel specifications; risk related to negative publicity or adverse media coverage that could damage our reputation and harm our business; risks related to our ability to maintain an effective nuclear-grade quality assurance program; risks related to the lack of a market for alternative low-carbon energy generation technologies which may grow slower than expected; risks related to our ability to manage our growth effectively to execute our business plan; risks related to disruptions or temporary shutdowns at any of our manufacturing facilities; risks relating to competition from existing or new competitors or technologies that could have downward pressure on prices, customer orders, reduced margins or our ability to take advantage of new business opportunities; risks related to the price of non-nuclear energy sources falling; risk related to the cost of electricity generated from nuclear sources not being competitive; risk related to our dependency on our management and key personnel for our success; risk related to the long development cycles of nuclear power generation projects which could impact customer demand for our nuclear fuel; risks related to the uncertainty to our forecasts of our costs estimates which are based on assumption which may not materialize; risks related to our capacity and other estimates not reflecting our actual future performance; risks relating to our customers’ ability to obtain HALEU; risks relating to the occurrence of a nuclear safety incident or nuclear accident that may change the course of the overall industry; risks related to the cancellation or delays of significant projects or cost structures and other negative announcements by competitors; risks related to the termination of the OTA due to shifts in governmental policy, priorities or oversight approach under the OTA; risks relating to the transition to NRC oversight from the DOE; risks related to our planned operations of the Richland facility which rely on our joint venture partner Framatome; risks related to the dissolution of our joint venture with Framatome if certain regulatory, operational or commercial milestones are not achieved; risks relating to the governance structure of the joint venture with Framatome which may result in deadlocks that could delay or prevent key decisions; risks related to the timing and size of contract awards and project milestones associated with a limited number of large contracts; risks related to our ability to compete in certain foreign markets; risks related to any allegation of infringement, misappropriation or violation of intellectual property or other proprietary rights of third parties; risk relating to our ability to obtain, maintain, protect or enforce our intellectual property and similar proprietary rights including our trade secrets; risks related to the U.S. government exercising march-in rights which could result in compulsory licensing of certain of our owned or licensed intellectual property; risks relating to our ability to keep pace with rapidly evolving technological developments in AI; risks relating to the direct or indirect impact of severe weather and other effects of climate on us and our customers; risks relating to the impact of any epidemics and other health related issues; risks relating to the actual costs and timelines around the production of advanced fuels and radioisotope power systems using non-uranium feedstocks may materially exceed estimates; risks relating to the occurrence of a cybersecurity incident or disruptions to or involving our information technology systems; risks relating to any change to government policy, laws, or requirements from one administration to another; risks relating to changes in federal, state, and local government policies and priorities; risks related to evolving regulations that may impose additional compliance costs or require design modifications; risks relating to safeguards and security requirements for special nuclear material that impose significant ongoing operational burdens and costs; risks relating to limitations or modifications to indemnification regulations of the United States or foreign countries; risks relating to export/import approvals or international agreements that restrict our business; risks relating to environmental reviews and potential litigation arising out of our operations that could delay projects or increase costs; risk relating to the transportation and disposal of toxic, hazardous and/or radiative materials; risk related to being subject to regulatory enforcement actions, safety culture concerns or quality program deficiencies; risks relating to professional liability, product liability and warranty and other claims; risks relating to changes in federal and state tax laws or interpretation thereof, and expiration of tax incentives and credits; risks relating to compliance with complex and evolving data privacy and cybersecurity laws, rules and regulations; risks relating to our potential legacy liability for Ultra Safe assets; risks relating to a creditor or other party challenging the Ultra Safe asset purchase transaction; risks relating to discovering title defects, liens or restrictions of title to Ultra Safe asset purchases; risks relating to environmental conditions, waste liabilities, or decommissioning obligations associated with the acquired assets; risks relating to most of our management team having limited experience managing a public company; risks relating to needing additional funding to fulfill our business plan; and the other factors set forth in our documents we have filed with the U.S. Securities and Exchange Commission (the “SEC”).

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties of the other documents filed by Standard Nuclear from time to time with the SEC. The forward-looking statements contained in this press release are based on current expectations and beliefs concerning future developments and their potential effects on Standard Nuclear. There can be no assurance that future developments affecting Standard Nuclear will be those that Standard Nuclear has anticipated. Standard Nuclear undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release, except as may be required by law.

Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this news release and in our filings with the SEC, including the Risk Factors in our most recent Registration Statement on Form S-1, in our future Quarterly Reports on Form 10-Q, and in our other filings with the SEC that attempt to advise interested parties of the risks and factors that may affect our business. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Standard Nuclear, Inc.

Unaudited Condensed Consolidated Statements of Operations

 

 

 

Three Months Ended June 30, 2026

 

Three Months Ended

June 30, 2025

 

Six Months Ended June 30, 2026

 

Six Months Ended June 30, 2025

Revenue

 

 

 

 

 

 

 

 

Product Revenue

 

$

3,100,000

 

 

$

 

 

$

3,101,741

 

 

$

 

Service Revenue

 

 

1,635,791

 

 

 

552,939

 

 

 

2,227,852

 

 

 

930,865

 

Total Revenue

 

 

4,735,791

 

 

 

552,939

 

 

 

5,329,593

 

 

 

930,865

 

Cost of Revenue

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

1,552,797

 

 

 

1,182,689

 

 

 

6,558,803

 

 

 

2,339,637

 

Total Cost of Revenue

 

 

1,552,797

 

 

 

1,182,689

 

 

 

6,558,803

 

 

 

2,339,637

 

Gross Profit (Loss)

 

 

3,182,994

 

 

 

(629,750

)

 

 

(1,229,210

)

 

 

(1,408,772

)

General and administrative costs

 

 

5,520,577

 

 

 

1,007,727

 

 

 

9,352,625

 

 

 

1,642,494

 

Research and development expenses

 

 

1,957,895

 

 

 

 

 

 

1,957,895

 

 

 

 

Loss from operations

 

 

(4,295,478

)

 

 

(1,637,477

)

 

 

(12,539,730

)

 

 

(3,051,266

)

Other expense (income):

 

 

 

 

 

 

 

 

Increase in fair value of SAFE Notes

 

 

 

 

 

 

 

 

 

 

 

7,725,000

 

Gain on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

 

(853,000

)

Interest income

 

 

(877,693

)

 

 

 

 

 

(1,406,994

)

 

 

 

Other expense (income)

 

 

 

 

 

(9,542

)

 

 

 

 

 

(9,542

)

Loss before income tax benefit

 

 

(3,417,785

)

 

 

(1,627,935

)

 

 

(11,132,736

)

 

 

(9,913,724

)

Income tax benefit

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(3,417,785

)

 

$

(1,627,935

)

 

$

(11,132,736

)

 

$

(9,913,724

)

Weighted average common shares outstanding – basic and diluted

 

 

28,001,802

 

 

 

28,000,000

 

 

 

28,000,906

 

 

 

28,000,000

 

Basic and diluted net loss per share

 

$

(0.12

)

 

$

(0.06

)

 

$

(0.40

)

 

$

(0.35

)

Standard Nuclear, Inc.

Unaudited Condensed Consolidated Balance Sheets

 

 

 

June 30,

2026

 

December 31,

2025

ASSETS

 

 

 

 

CURRENT ASSETS:

 

 

 

 

Cash and cash equivalents

 

$

102,185,333

 

 

$

63,101,704

 

Accounts receivable and contract assets, net

 

 

8,128,817

 

 

 

2,291,671

 

Deferred transaction costs

 

 

2,135,079

 

 

 

0

 

Prepaid and other current assets

 

 

646,981

 

 

 

0

 

Total current assets

 

$

113,096,210

 

 

$

65,393,374

 

Property and equipment, net

 

 

31,375,038

 

 

 

12,627,624

 

Investment in Joint Venture

 

 

2,481,829

 

 

 

1,130,170

 

TOTAL ASSETS

 

$

146,953,077

 

 

$

79,151,167

 

 

 

 

 

 

LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ DEFICIT

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

Accounts payable

 

$

4,567,617

 

 

$

2,082,547

 

Accrued and other liabilities

 

 

148,148

 

 

 

354,601

 

Deferred revenue

 

 

4,031,783

 

 

 

1,076,531

 

Total current liabilities

 

$

8,747,548

 

 

$

3,513,679

 

Asset retirement obligations

 

 

795,254

 

 

 

753,223

 

TOTAL LIABILITIES

 

$

9,542,802

 

 

$

4,266,902

 

 

 

 

 

 

Mezzanine equity:

 

 

 

 

Redeemable preferred stock, 116,141,488 shares authorized, issued and outstanding at June 30, 2026 and 101,948,458 shares authorized, issued and outstanding at December 31, 2025; redemption value $214,999,997 and $144,999,977 at June 30, 2026 and December 31, 2025, respectively (1)

 

$

214,999,997

 

 

$

144,999,977

 

 

 

 

 

 

Stockholders’ Deficit:

 

 

 

 

Ordinary shares, $0.00001 par value; 0 shares authorized, issued and outstanding at June 30, 2026 and December 31, 2025

 

$

 

 

$

 

Class A Common Stock, $0.00001 par value; 175,000,000 shares authorized at June 30, 2026 and December 31, 2025; 14,504,000 shares issued and outstanding at June 30, 2026 and December 31, 2025 (1)

 

 

145

 

 

 

145

 

Class B Convertible Common Stock, $0.00001 par value; 35,615,000 shares authorized at June 30, 2026 and December 31, 2025; 13,630,998 shares and 13,496,000 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively (1)

 

 

135

 

 

 

135

 

Additional paid-in capital

 

 

5,680,085

 

 

 

2,021,359

 

Accumulated deficit

 

 

(83,270,087

)

 

 

(72,137,351

)

Total Stockholders’ Deficit

 

$

(77,589,722

)

 

$

(70,115,712

)

Total Liabilities, Mezzanine Equity, and Stockholders’ Deficit

 

$

146,953,077

 

 

$

79,151,167

 

 

(1) All share amounts above have been retrospectively adjusted to reflect the 2-for-1 stock split effected July 6, 2026.

Standard Nuclear, Inc.

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit

 

 

Class A

Common Stock

 

Class B

Common Stock

 

Ordinary shares

 

Additional

Paid-in

Capital

 

Accumulated

Deficit

 

Total

Stockholders’

Deficit

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

 

 

Balances as of December 31, 2024

 

$

 

 

$

 

28,000,000

 

 

$

280

 

 

$

279,720

 

$

(56,596,406

)

 

$

(56,316,406

)

Conversion of Ordinary Shares to Class A and Class B Common Stock

14,504,000

 

 

145

 

13,496,000

 

 

135

 

(28,000,000

)

 

 

(280

)

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,285,791

)

 

 

(8,285,791

)

Balances as of March 31, 2025

14,504,000

 

$

145

 

13,496,000

 

$

135

 

 

 

$

 

 

$

279,720

 

$

(64,882,197

)

 

$

(64,602,197

)

Share-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

175,702

 

 

 

 

 

175,702

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,627,935

)

 

 

(1,627,935

)

Balances as of June 30, 2025

14,504,000

 

$

145

 

13,496,000

 

$

135

 

 

 

$

 

 

$

455,422

 

$

(66,510,132

)

 

$

(66,054,430

)

 

Class A

Common Stock

 

Class B

Common Stock

 

Ordinary shares

 

Additional

Paid-in

Capital

 

Accumulated

Deficit

 

Total

Stockholders’

Deficit

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

 

 

Balances as of December 31, 2025

14,504,000

 

$

145

 

13,496,000

 

$

135

 

 

$

 

$

2,021,359

 

$

(72,137,351

)

 

$

(70,115,712

)

Share-based compensation

 

 

 

 

 

 

 

 

 

 

1,509,297

 

 

 

 

 

1,509,297

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(7,714,951

)

 

 

(7,714,951

)

Balances as of March 31, 2026

14,504,000

 

$

145

 

13,496,000

 

$

135

 

 

$

 

$

3,530,656

 

$

(79,852,302

)

 

$

(76,321,366

)

Share-based compensation

 

 

 

 

 

 

 

 

 

 

2,148,205

 

 

 

 

 

2,148,205

 

Exercise of stock options

 

 

 

134,998

 

 

 

 

 

 

 

1,224

 

 

 

 

 

1,224

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(3,417,785

)

 

 

(3,417,785

)

Balances as of June 30, 2026

14,504,000

 

$

145

 

13,630,998

 

$

135

 

 

$

 

$

5,680,085

 

$

(83,270,087

)

 

$

(77,589,722

)

Standard Nuclear, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

 

 

Six Months Ended June 30, 2026

 

Six Months Ended June 30, 2025

Cash flows from operating activities

 

 

 

Net loss

$

(11,132,736

)

 

$

(9,913,724

)

Adjustments to reconcile net loss to net cash flows from operating activities:

 

 

 

Share-based compensation expense

 

3,657,502

 

 

 

175,702

 

Depreciation expense

 

598,881

 

 

 

58,292

 

Change in fair value of SAFE Notes liability

 

 

 

 

7,725,000

 

Gain on extinguishment of SAFE Notes

 

 

 

 

(853,000

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable and contract assets, net

 

(5,837,146

)

 

 

(312,810

)

Prepaid and other current assets

 

(646,981

)

 

 

(31,250

)

Accounts payable

 

(367,886

)

 

 

298,994

 

Accrued expenses and other liabilities

 

(164,422

)

 

 

66,516

 

Deferred revenue

 

2,955,252

 

 

 

27,212

 

Net cash used in operating activities

$

(10,937,536

)

 

$

(2,759,068

)

 

 

 

 

Cash flows from investing activities

 

 

 

Purchases of property and equipment

$

(17,419,069.00

)

 

$

(554,743.00

)

Contributions to equity method investment

 

(425,931

)

 

 

 

Net cash used in investing activities

$

(17,845,000.00

)

 

$

(554,743.00

)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issuance of convertible redeemable preferred shares

$

70,000,020

 

 

$

 

Exercise of stock options

 

1,224

 

 

 

 

Payment of deferred transaction costs

 

(2,135,079

)

 

 

Proceeds from issuance of Series Seed preferred stock, net of issuance costs

 

 

 

 

7,945,686

 

Net cash provided by financing activities

$

67,866,165.00

 

 

$

7,945,686.00

 

 

 

 

 

Net increase in cash and cash equivalents

 

39,083,629

 

 

 

4,631,875

 

Cash and cash equivalents at beginning of period

 

63,101,704

 

 

 

1,619,817

 

Cash and cash equivalents at end of period

$

102,185,333

 

 

$

6,251,692

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

Cash paid for interest

$

 

 

$

 

Cash paid for income taxes

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

 

Conversion of SAFE Notes into Series Seed-1 Preferred stock

$

 

 

$

32,500,000

 

Reclassification of SAFE Notes fair value to mezzanine equity upon conversion

 

 

 

 

32,500,000

 

Extinguishment of SAFE Notes (reduction of SAFE liability)

 

 

 

 

1,000,000

 

Reclassification of short-term cash advances to Series Seed preferred stock

 

 

 

 

2,494,833

 

Investment in joint venture included in accounts payable

 

925,729

 

 

 

 

Property and equipment purchases included in accounts payable

 

1,927,226

 

 

 

44,406

 

 

Investors Contact:

[email protected]

Media Contact:

[email protected]

KEYWORDS: Tennessee United States North America

INDUSTRY KEYWORDS: Nuclear Energy Other Energy Utilities

MEDIA:

Logo
Logo

Teledyne FLIR Marine Introduces FLIR M364C-USV Camera for Autonomous and Uncrewed Vessels

Teledyne FLIR Marine Introduces FLIR M364C-USV Camera for Autonomous and Uncrewed Vessels

Purpose-built multispectral maritime camera system helps autonomous and uncrewed vessel operators navigate safely, detect hazards earlier and accelerate deployment of next-generation maritime autonomy solutions

HUDSON, N.H.–(BUSINESS WIRE)–Teledyne FLIR Marine, part of Teledyne Technologies Incorporated (NYSE: TDY), today introduced the FLIR M364C-USV, a multispectral maritime camera system designed to help autonomous and uncrewed surface vessel (USV) operators navigate safely, detect hazards sooner and maintain situational awareness in demanding marine environments. Combining thermal and visible imaging in a rugged, mission-ready platform, the M364C-USV enables reliable operation day or night and in challenging conditions such as glare, haze and low visibility.

Built specifically for remote, autonomous and uncrewed operations, the M364C-USV delivers the clear, actionable imagery needed for navigation, obstacle avoidance, surveillance, security, environmental monitoring and scientific research. Its reinforced pan-and-tilt system and continuous-duty design help ensure critical visual intelligence remains available throughout extended missions.

“Autonomous and uncrewed vessels depend on reliable sensing technologies to operate safely and effectively in dynamic maritime environments,” said Michelle Hildyard, General Manager of Teledyne FLIR Marine. “The M364C-USV delivers the real-time visibility and situational awareness operators need to make better decisions, avoid hazards and support mission success, while providing the durability required for continuous operation at sea.”

Designed specifically for autonomous and uncrewed vessel applications, the M364C-USV helps developers accelerate deployment by simplifying integration with autonomy, remote-control and mission-management systems. The camera delivers high-quality thermal and visible imagery that supports advanced analytics, AI-enabled workflows and machine-vision applications, while aligned video and telemetry data provide more reliable inputs for tracking, navigation and situational awareness. Combined with a design that is built for demanding marine environments, the M364C-USV gives operators a dependable imaging solution for long-duration autonomous missions.

The M364C-USV helps vessel operators maintain awareness and navigate successfully in changing environmental conditions. By combining thermal and visible imaging, the camera system improves the detection of vessels, navigation markers and other obstacles during daylight, darkness and low-visibility conditions, helping support safer and more effective operations.

M364C-USV camera systems are available to order now and are backed by a two-year limited warranty tailored to the continuous, high-duty-cycle operating profiles typical of USV platforms.

To learn more about the Teledyne FLIR M364C-USV camera and Teledyne FLIR Marine’s complete portfolio of maritime imaging solutions, visit marine.flir.com.

About Teledyne FLIR Marine

Teledyne FLIR Marine is a global leader in marine thermal imaging, delivering advanced camera solutions that enhance safety and situational awareness for mariners in all conditions. Its systems provide clear, reliable vision in darkness, glare and challenging weather conditions, supporting safer navigation for commercial operators, first responders and recreational boaters. The portfolio includes advanced thermal and low-light imaging technologies designed specifically for demanding marine environments. To learn more, visit marine.flir.com.

About Teledyne Technologies

Teledyne Technologies is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne’s operations are primarily located in the United States, the United Kingdom, Canada, and Western and Northern Europe. For more information, visit Teledyne’s website at www.teledyne.com.

For high-resolution images, as well as additional editorial requests, please contact:

Andrew Golden
Principal
Rushton Gregory Communications
617-413-6521
[email protected]

KEYWORDS: New Hampshire United States North America

INDUSTRY KEYWORDS: Technology Maritime Security Transport Military Photography Audio/Video Hardware Defense

MEDIA:

Logo
Logo

Ibotta to Participate in Upcoming Investor Conferences

Ibotta to Participate in Upcoming Investor Conferences

DENVER–(BUSINESS WIRE)–
Ibotta, Inc. (NYSE: IBTA), the performance marketing platform for promotions, announced today that company executives will participate in the following investor events:

  • On September 9, 2026 at 7:50 a.m. PT/10:50 a.m. ET, Chief Financial Officer Matt Puckett will participate in a fireside chat at Citi’s 2026 Global TMT Conference in New York. A webcast of the event will be available here.

  • On September 10, 2026 at 2:25 p.m. PT/5:25 p.m. ET, Chief Revenue Officer Chris Riedy will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference 2026 in San Francisco. A webcast of the event will be available here.

Audio webcasts will also be available on the investor relations section of the Ibotta website at investors.ibotta.com.

About Ibotta (“I bought a…”)

Ibotta (NYSE: IBTA) is the leading provider of digital promotions for CPG brands, reaching over 200 million consumers through a network of publishers called the Ibotta Performance Network (IPN). The IPN allows marketers to influence what people buy, and where and how often they shop – all while paying only when their campaigns directly result in a sale. American shoppers have earned over $2.9 billion through the IPN since 2012. Ibotta is headquartered in Denver and has been listed as a top place to work by The Denver Post and Inc. Magazine.

Corporate Communications

Christopher Boyd, [email protected]

Investor Relations

Shalin Patel, [email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Software Other Retail Online Retail Internet Electronic Commerce Apps/Applications Technology Digital Marketing Retail Marketing Advertising Content Marketing Communications

MEDIA:

Logo
Logo

Perma-Pipe to Report Second Quarter 2026 Results and Host Investor Conference Call on Wednesday, September 9, 2026

Perma-Pipe to Report Second Quarter 2026 Results and Host Investor Conference Call on Wednesday, September 9, 2026

THE WOODLANDS, Texas–(BUSINESS WIRE)–
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH), today announced it will release its second quarter 2026 financial results on Wednesday, September 9, 2026, before the market opens.

Management will host a conference call and webcast at 7:30 a.m. Central Time/ 8:30 a.m. Eastern Time on the same day.

How to participate:

  • Dial (877) 317-6789 domestically and (412) 317-6789 internationally 20 minutes prior to the scheduled call time. Please ask to join Perma-Pipe call.

  • Access the live webcast at link.

A replay of the webcast will be archived on the Perma-Pipe website for approximately one year. An audio replay of the conference call will be available through Wednesday, September 16, 2026, and can be accessed by dialing (855) 669-9658 or (412) 317-0088 and entering conference ID 2085365.

Perma-Pipe International Holdings, Inc.

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) is a global leader in engineered piping and corrosion protection solutions. The Company provides pre-insulated piping systems, leak detection systems, anti-corrosion coatings and related engineered products and services to customers across the energy, district energy, infrastructure, industrial, Oil & Gas, water transmission, and other critical infrastructure markets.

Perma-Pipe operates manufacturing and service facilities across North America, Middle East, North Africa, India and other strategic markets, enabling the Company to serve customers globally while providing local manufacturing and engineering capabilities.

Saleh Sagr, President and CEO

Perma-PipeInvestor Relations

847.929.1200

[email protected]

KEYWORDS: Texas United States North America Canada

INDUSTRY KEYWORDS: Other Manufacturing Construction & Property Engineering Other Energy Chemicals/Plastics Utilities Manufacturing Building Systems Energy

MEDIA:

Logo
Logo

Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions

AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care.

“Higgs Boson employs highly experienced teams of software developers and AI scientists who will be joining our team to power our vision of a seamless digital healthcare environment to simplify a patient’s journey through our healthcare system while enhancing real-time information and surgical intelligence available to healthcare providers with the ultimate goal of getting to 95% good outcomes at 10 years for all musculoskeletal surgeries,” said David Paul, Founder and Executive Chairman.

“The acquisition of Higgs Boson and its digital solutions represents the next step in our strategy of enhancing the Globus ecosystem,” commented Keith Pfeil, President and Chief Executive Officer. “As we continue to build out the ecosystem, the Higgs Boson technology will be part of our surgical intelligence pillar, bringing together outcomes and analytics in a closed-loop manner that fosters continuous learning, integrating along the full patient journey with the goal of improving patient outcomes.”

About Globus Medical, Inc.

Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.

Contact:

Brian Kearns
Senior Vice President, Corporate Development and Investor Relations
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com